Grantham, Mayo, Van Otterloo & Co (GMO)
ALXN

Grantham, Mayo, Van Otterloo & Co (GMO)’s Alexion Pharmaceuticals ALXN Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-528,033
Closed -$97M – 791
2021
Q2 		$97M Sell
528,033
-141,290
-21% -$24.3M 0.48% 45
2021
Q1 		$102M Buy
669,323
+397,440
+146% +$61.5M 0.56% 41
2020
Q4 		$42.5M Buy
+271,883
New +$34.9M 0.26% 60
2013
Q3 		– Sell
-69,727
Closed -$6.43M – 704
2013
Q2 		$6.43M Buy
+69,727
New +$6.72M 0.02% 259

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s ALXN Position: Q3 2021 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 528,033 shares — an estimated $97M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ALXN in Q2 2013 and held it in 4 quarters. The position peaked at $102M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 528,033 Alexion Pharmaceuticals shares in Q3 2021, an estimated $97M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Alexion Pharmaceuticals position peaked at $102M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2021, filed 12 Nov 2021.